Technical Analysis for OPK - OPKO Health Inc.
|Grade||Last Price||% Change||Price Change|
OPK closed down 0.27 percent on Thursday, January 17, 2019, on 79 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical OPK trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||Doji - Bullish?||Reversal||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Overbought Stochastic||Strength||0.00%|
|Jan 16||Wide Bands||Range Expansion||-0.27%|
|Jan 16||Overbought Stochastic||Strength||-0.27%|
|Jan 15||180 Bullish Setup||Bullish Swing Setup||-1.59%|
|Jan 15||NR7||Range Contraction||-1.59%|
|Jan 15||Wide Bands||Range Expansion||-1.59%|
|Jan 15||Overbought Stochastic||Strength||-1.59%|
|Jan 14||Wide Bands||Range Expansion||0.54%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more OPK news...
|52 Week High||6.4|
|52 Week Low||2.34|
|200-Day Moving Average||4.0972|
|50-Day Moving Average||3.3768|
|20-Day Moving Average||3.269|
|10-Day Moving Average||3.699|
|Average True Range||0.2419|
|Chandelier Exit (Long, 3 ATRs )||3.2043|
|Chandelier Exit (Short, 3 ATRs )||3.0657|
|Upper Bollinger Band||4.24|
|Lower Bollinger Band||2.298|
|Percent B (%b)||0.73|
|MACD Signal Line||0.0818|
|Market Cap||2.08 Billion|
|Num Shares||559 Million|
|Price-to-Earnings (P/E) Ratio||-24.80|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||3.93|
|Resistance 3 (R3)||3.92||3.85||3.90|
|Resistance 2 (R2)||3.85||3.79||3.85||3.88|
|Resistance 1 (R1)||3.78||3.76||3.82||3.79||3.87|
|Support 1 (S1)||3.64||3.65||3.68||3.65||3.57|
|Support 2 (S2)||3.57||3.62||3.57||3.56|
|Support 3 (S3)||3.50||3.57||3.55|
|Support 4 (S4)||3.51|